CATHETER PRECISION INC (VTAK)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
$0.65+3.17%
Close 2026-10-29 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · VTAK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -69.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 100.0% |
Growth built into the price is above our model estimate.
The price assumes 169.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 43 industry peers
VTAK — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-10-09
Unregistered Sales of Equity Securities. On October 9, 2026, pursuant to the Additional Investment Right under the Securities Purchase Agreement, dated as of March 9, 2026, by and among Flyte Aviation, Inc. (formerly known as Catheter Precision, Inc.) (the “Company”) and the investors party thereto (the “Purchase Agreement”), which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 9, 2026, certain exist…
Why it matters: The Q1 release said medical device sales grew 73%, while Q3 MedTech revenue reached about $280,000. Continued growth would show demand beyond aviation.
Supportive ifThe next quarterly report shows MedTech revenue above about $280,000 in Q3. It also shows VIVO or LockeT adoption at new institutions.
Worry ifThe next quarterly report shows MedTech revenue at or below about $280,000. It reports no adoption at new institutions.
Why it matters: Flyte said new aircraft could support growth in Q4. Higher aviation sales would show that the fleet is bringing in more revenue.
Supportive ifReported Q4 aviation revenue is above about $1.87 million in Q3.
Worry ifReported Q4 aviation revenue is about $1.87 million or less, matching Q3.
Why it matters: The company remains loss-making, and recent stock sales add to funding concerns. A smaller loss would show that rising revenue is helping cover costs.
Supportive ifThe Q3 filing reports a net loss below $1.7 million.
Worry ifThe Q3 filing reports a net loss of $1.7 million or more.
Why it matters: The October release called this result preliminary. The November 12 report can show if fast sales growth continued.
Supportive ifThe November 12 report confirms Q3 revenue at or above $2.15 million.
Worry ifThe final Q3 report puts revenue below $2.15 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$459 on $10,000 · ±4.6% | How much price usually moves either way. |
| Bad day | $1,294 loss on $10,000 · 12.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,790 loss on $10,000 · 97.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Canada would extend Flyte's flight network beyond its current routes. Permits and launched flights would show that this expansion is real.
Supportive ifFlyte announces it has the required permits. It confirms flights to or within Canada have begun.
Worry ifFlyte reports that permits are still pending, or that service has not started by its next quarterly report.
Why it matters: The multi-year deal offers ways to reach fans and business customers, but its sales impact is not yet known. Bookings would show whether the partnership brings paying customers.
Supportive ifFlyte reports bookings or revenue linked to the 76ers partnership, or names a paying customer gained through it.
Worry ifFlyte reports no bookings or revenue linked to the deal by its next quarterly report.